GlaxoSmithKline has been fined £37.6 million for striking deals with potential rivals to delay their launch of generic copies of its drug for anxiety disorders and depression.
The Competition Market Authority's Michael Grenfell told ITV News that GSK's actions had inflated the price of the antidepressant Seroxat and cost the NHS and taxpayer.
GSK argued its actions had brought down the cost of medicine for the NHS.
The drugmaker said it strongly disagreed with the regulator's fine for market abuse and was considering grounds for appeal.
Other drug companies involved were also fined smaller amounts, bringing the total fines issued by the CMA to £45 million.
Sir Philip Hampton, who has been chairman of Royal Bank of Scotland since 2009, is to leave the bank next year for the same role at GlaxoSmithKline.
GlaxoSmithKline has been fined £297 million and its former country manager handed a suspended prison sentence in China for bribery.
GSK accepted the decision by the Changsha Intermediate People's Court in Hunan province that it had bribed doctors and hospitals to use its products, adding it has taken steps to change its working practices.
ITV News China Correspondent Lucy Watson reports from Beijing:
Mark Reilly, the former China head of British drugmaker GlaxoSmithKline, will be deported from China and will not face jail time in the country, Reuters has reported citing a source with direct knowledge of the matter.
"Reilly will be deported so he won't be in detention in China," said the source with knowledge of the matter who declined to be named because of the sensitivity of the case.
A fine of £297 million for drug giant GlaxoSmithKline has not worried investors, with shares in GSK rising 0.8%, or 11p, to £14.47 in morning trading in London.
GlaxoSmithKline said a bribery case in China had been a "deeply disappointing matter" after a number of company executives were jailed and the firm was fined £297 million.
GSK said in a statement on their website that the activities by the firm's China unit were a "clear breach" of GSK's governance and compliance procedures.
GSK Chief Executive Officer Sir Andrew Witty said:
Reaching a conclusion in the investigation of our Chinese business is important, but this has been a deeply disappointing matter for GSK. We have and will continue to learn from this.
GSK has been in China for close to a hundred years and we remain fully committed to the country and its people. We will continue to expand access to innovative medicines and vaccines to improve their health and well-being.
We will also continue to invest directly in the country to support the government's health care reform agenda and long-term plans for economic growth.
Former GlaxoSmithKline China chief Mark Reilly and other GSK executives will be jailed for two to four years for paying out bribes, state news agency Xinhua said.
China has fined British pharmaceuticals giant three billion yuan (£297 million) in what is a record penalty for China, Xinhua said.
China has fined British drug firm GlaxoSmithKline $492 million and jailed company executives on bribery charges, the Associated Press has reported.
BREAKING: China fines British drug maker GlaxoSmithKline $492 million, jails executives in bribery case
The first human trials of a potential Ebola vaccine could begin in the Oxford as early as mid-September.
The candidate vaccine has been being developed by the US National Institutes of Health and pharmaceutical giant GlaxoSmithKline. Funding from a consortium of British bodies has allowed the UK trials to be fast-tracked.
Professor Adrian Hill, who will be running the trials at Oxford University, said he was looking for 60 healthy individuals aged 18 to 50 to take part in the study. Volunteers will have to make nine visits over six months and will receive modest compensation for their time.
Unlike with vaccines for some other illnesses, it does not contain any infectious virus material, so it "cannot cause a person who is vaccinated to become infected with Ebola," GlaxoSmithKline said in a statement.
Manufacturers are planning to produce around 10,000 doses of the potential vaccine that will be distributed to "high-risk communities" if the trials prove successful. Other trials are being planned in the US, Gambia and Mali.